Overview

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:
0

Participant gender:
All

Summary

The goal of this clinical research study is to see if receiving a transplant of blood stem cells (cells that can produce blood) or bone marrow from either a related donor (brother, sister or other relative) or an unrelated voluntary donor will help patients with advanced cutaneous T-cell lymphoma. The length of time that patients who receive the treatment remain free of disease will also be studied.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Antilymphocyte Serum
Fludarabine
Fludarabine phosphate
Melphalan
Thymoglobulin
Vidarabine

Criteria

Inclusion Criteria:

1. Patients with pathologically proven cutaneous T-cell lymphoma (CTCL), disease stage
IIB to IVB, patients must be in at least a partial response-PR (skin and lymph nodes)
after receiving other non-allogeneic transplant therapy, age performance status 0 or 1, left ventricular ejection fraction >/= 50% or approved for
transplant by a cardiologist, DLCO >/= 50% predicted or approved for transplant by a
pulmonologist, serum creatinine upper limit of normal, and no previous history of allogeneic transplantation.

2. Donor: HLA-compatible related (HLA-A, -B, -DRB1 matched or with one-antigen mismatch)
or HLA-compatible unrelated (HLA-A, -B, -C and -DRB1 matched or with one-antigen
mismatch).

Exclusion Criteria:

1) Patients cannot have active central nervous system (CNS) disease.